[go: up one dir, main page]

PT960107E - Compostos de paclitaxel 6-tio-substituidos - Google Patents

Compostos de paclitaxel 6-tio-substituidos

Info

Publication number
PT960107E
PT960107E PT97954044T PT97954044T PT960107E PT 960107 E PT960107 E PT 960107E PT 97954044 T PT97954044 T PT 97954044T PT 97954044 T PT97954044 T PT 97954044T PT 960107 E PT960107 E PT 960107E
Authority
PT
Portugal
Prior art keywords
tio
substituted paclitaxel
paclitaxel compounds
compounds
substituted
Prior art date
Application number
PT97954044T
Other languages
English (en)
Inventor
Dolatrai M Vyas
Mark D Wittman
John F Kadow
Andrew J Staab
Harold A Mastalerz
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT960107E publication Critical patent/PT960107E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D305/00Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6551Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring
    • C07F9/65512Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a four-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Cephalosporin Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
PT97954044T 1996-12-24 1997-12-05 Compostos de paclitaxel 6-tio-substituidos PT960107E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3341996P 1996-12-24 1996-12-24
US3635197P 1997-01-23 1997-01-23

Publications (1)

Publication Number Publication Date
PT960107E true PT960107E (pt) 2003-02-28

Family

ID=26709670

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97954044T PT960107E (pt) 1996-12-24 1997-12-05 Compostos de paclitaxel 6-tio-substituidos

Country Status (11)

Country Link
US (1) US5977386A (pt)
EP (1) EP0960107B1 (pt)
JP (1) JP2001507029A (pt)
AT (1) ATE225341T1 (pt)
AU (1) AU722684B2 (pt)
CA (1) CA2268774A1 (pt)
DE (1) DE69716135T2 (pt)
DK (1) DK0960107T3 (pt)
ES (1) ES2184149T3 (pt)
PT (1) PT960107E (pt)
WO (1) WO1998028288A1 (pt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1229934B1 (en) 1999-10-01 2014-03-05 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6362217B2 (en) 2000-03-17 2002-03-26 Bristol-Myers Squibb Company Taxane anticancer agents
CA2410632A1 (en) 2000-06-22 2001-12-27 David S. Garvey Nitrosated and nitrosylated taxanes, compositions and methods of use
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
DK2286795T3 (en) 2002-06-26 2017-02-06 Syncore Biotechnology Co Ltd PROCEDURE FOR PREPARING A Cationic LIPOSOMAL PREPARATION INCLUDING A LIPOPHIL COMPOUND
WO2005016241A2 (en) 2003-05-16 2005-02-24 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2006089218A2 (en) 2005-02-17 2006-08-24 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating angiogenesis
CA2922029C (en) 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
PL217731B1 (pl) 2006-06-01 2014-08-29 Tomasz Byrski Sposób wykrywania genetycznie uwarunkowanej obniżonej odpowiedzi na chemioterapię cytostatykiem taksanowym, zastosowanie mutacji założycielskiej oraz zestawu do wykrywania takiej odpowiedzi
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
WO2010005850A1 (en) 2008-07-08 2010-01-14 The J. David Gladstone Institutes Methods and compositions for modulating angiogenesis
CN102040570B (zh) * 2009-10-14 2014-07-30 江苏先声药物研究有限公司 硫代紫杉烷类衍生物及其制备方法和用途
IN2015DN00552A (pt) 2012-07-19 2015-06-26 Redwood Bioscience Inc
CN104884056A (zh) 2012-11-12 2015-09-02 雷德伍德生物科技股份有限公司 用于制备缀合物的化合物和方法
DK3300745T3 (da) 2013-02-15 2019-11-04 Univ California Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf
WO2014160185A2 (en) 2013-03-14 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
EP3074010A4 (en) 2013-11-27 2017-10-25 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
WO2015127137A1 (en) 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
JP2017511376A (ja) 2014-03-21 2017-04-20 アッヴィ・インコーポレイテッド 抗egfr抗体及び抗体薬物コンジュゲート
EP3373977A4 (en) 2015-11-12 2019-07-17 The Board of Trustees of the Leland Stanford Junior University CELL-PENETRATING, GUANIDINIUM-LICH OLIGOPHOSPHOTRIESTER FOR ACTIVE AND SPILL-RELIEF
EP3377523A4 (en) 2015-11-19 2019-06-19 The Regents of The University of California CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
EP3231421A1 (en) 2016-04-11 2017-10-18 Greenaltech, S.L. Uses of a carotenoid in the treatment or prevention of stress induced conditions
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
BR112018074823B1 (pt) 2016-06-01 2024-02-27 Servier IP UK Limited Composições liofilizadas, método de produção de uma composição, uso das composições e kit
RU2764651C2 (ru) 2016-06-08 2022-01-19 Эббви Инк. Антитела к в7-н3 и конъюгаты антитела и лекарственного средства
MX2018015285A (es) 2016-06-08 2019-09-18 Abbvie Inc Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
WO2017214322A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-b7-h3 antibodies and antibody drug conjugates
MX2018015272A (es) 2016-06-08 2019-08-12 Abbvie Inc Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
WO2017214456A1 (en) 2016-06-08 2017-12-14 Abbvie Inc. Anti-cd98 antibodies and antibody drug conjugates
TWI852903B (zh) 2017-01-05 2024-08-21 杏國新藥股份有限公司 胰臟癌治療
MX2019008503A (es) 2017-01-18 2019-09-13 F1 Oncology Inc Receptores de antigenos quimericos contra axl o ror2 y metodos de uso de los mismos.
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CN110003142A (zh) * 2018-01-04 2019-07-12 深圳福山生物科技有限公司 一种硒氰化合物及其用途
JP2021512110A (ja) 2018-01-31 2021-05-13 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法
EP3773671A4 (en) 2018-04-11 2022-03-09 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR RETARDED MICROPARTICLES FOR EYE DRUG DELIVERY
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
KR20220004653A (ko) 2019-04-02 2022-01-11 켄조케티 바이오테크놀러지 인코포레이티드 유출 펌프-암 항원 다중특이적 항체 및 그것과 관련된 조성물, 시약, 키트 및 방법
BR112022013870A2 (pt) 2020-01-29 2022-09-13 Kenjockety Biotechnology Inc Anticorpos anti-mdr1 e usos dos mesmos
EP4161650A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
EP4161564A1 (en) 2020-06-04 2023-04-12 Kenjockety Biotechnology, Inc. Abcg2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
EP4208483A1 (en) 2020-09-02 2023-07-12 Kenjockety Biotechnology, Inc. Anti-abcc1 antibodies and uses thereof
CA3203652A1 (en) 2020-11-13 2022-05-19 William Robert ARATHOON Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
US12187810B2 (en) 2020-11-20 2025-01-07 R.P. Scherer Technologies, Llc Glycoside dual-cleavage linkers for antibody-drug conjugates
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
US4876399A (en) * 1987-11-02 1989-10-24 Research Corporation Technologies, Inc. Taxols, their preparation and intermediates thereof
US4960790A (en) * 1989-03-09 1990-10-02 University Of Kansas Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof
US5714512A (en) * 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
ES2141727T3 (es) * 1991-09-23 2000-04-01 Univ Florida State Derivados de 10-desacetoxitaxol.
US5272171A (en) * 1992-02-13 1993-12-21 Bristol-Myers Squibb Company Phosphonooxy and carbonate derivatives of taxol
WO1993021173A1 (en) * 1992-04-17 1993-10-28 Abbott Laboratories Taxol derivatives
US5254580A (en) * 1993-01-19 1993-10-19 Bristol-Myers Squibb Company 7,8-cyclopropataxanes
US5294637A (en) * 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
FR2697019B1 (fr) * 1992-10-15 1994-11-25 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
CA2109861C (en) * 1992-12-04 1999-03-16 Shu-Hui Chen 6,7-modified paclitaxels
NZ261070A (en) * 1992-12-23 1997-10-24 Bristol Myers Squibb Co Oxazoline-substituted taxane derivatives and their preparation; intermediates
CA2111527C (en) * 1992-12-24 2000-07-18 Jerzy Golik Phosphonooxymethyl ethers of taxane derivatives
JP3892481B2 (ja) * 1993-03-05 2007-03-14 フロリダ・ステート・ユニバーシティー 9−デスオキソタキサンの製法
US5703247A (en) * 1993-03-11 1997-12-30 Virginia Tech Intellectual Properties, Inc. 2-Debenzoyl-2-acyl taxol derivatives and methods for making same
EP0982301B1 (en) * 1993-06-11 2003-09-10 PHARMACIA & UPJOHN COMPANY Delta 6,7-taxols antineoplastic use and pharmaceutical compositions containing them
EP0764643A1 (en) * 1994-06-09 1997-03-26 Daiichi Pharmaceutical Co., Ltd. Deacetoxytaxol derivative
DK0767786T3 (da) * 1994-06-28 1999-06-14 Upjohn Co 7-ether-taxol-analoge, antineoplastisk anvendelse deraf og farmaceutiske præparater indeholdende disse forbindelser
DE69507702T2 (de) * 1994-07-26 1999-08-26 Indena S.P.A. Semisynthetisch taxal derivate mit antitumor wirkung

Also Published As

Publication number Publication date
ATE225341T1 (de) 2002-10-15
EP0960107A4 (pt) 1999-12-01
AU722684B2 (en) 2000-08-10
DE69716135D1 (en) 2002-11-07
US5977386A (en) 1999-11-02
DK0960107T3 (da) 2003-02-10
EP0960107A1 (en) 1999-12-01
JP2001507029A (ja) 2001-05-29
EP0960107B1 (en) 2002-10-02
WO1998028288A1 (en) 1998-07-02
AU5792298A (en) 1998-07-17
ES2184149T3 (es) 2003-04-01
DE69716135T2 (de) 2003-06-05
CA2268774A1 (en) 1998-07-02

Similar Documents

Publication Publication Date Title
PT960107E (pt) Compostos de paclitaxel 6-tio-substituidos
NO943002D0 (no) Fosfono-oksymetyletere av taxanderivater
PT971717E (pt) Amino-acucar citotoxico e derivados de acucar afins de indolopirrolocarbazois
ATE231872T1 (de) Thiazolopyrimidinderivate
ES2181744T3 (es) Hidratos de paclitaxel cristalinos.
ID23374A (id) Halogenopirimidin
ES2147739T3 (es) Fosfonooximetil-eteres de derivados de taxano.
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
TR199800436A3 (tr) Primidin türevlerinin kanserin önlenmesi için kullanilmasi.
HK1030218A1 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same.
MX9601994A (es) Profarmacos de derivados de paclitaxel.
CA2152771A1 (en) 7-o-ethers of taxane derivatives
SE9802937D0 (sv) Novel compounds
DK1073447T3 (da) N1-modificerede glycopeptider
PT1011329E (pt) Paclitaxeis de 7-metiltio-oxometilo e 7-metiltiodioxometilo
AU4558201A (en) Taxane anticancer agents
TWI231815B (en) Glycopeptide derivatives and pharmaceutical compositions containing the same for use as antibacterial agents
ECSP003536A (es) Derivados de rufomicina utiles como antibioticos